JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $7

Benzinga · 1d ago
JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $10 to $7.